close message

GET PATIENTS STARTED AT NO CHARGE

Some exclusions apply.

LEMS EDUCATIONAL VIDEO LIBRARY

Why LEMS in Adults Warrants a Closer Look: Clinical Insights and Common Misdiagnoses

This educational video series describes the clinical presentation of Lambert-Eaton myasthenic syndrome (LEMS), the challenges of diagnosis, and the role that FIRDAPSE® can play in treatment. This content was featured in a presentation delivered at the 2019 Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine.

CHAPTER 1 – LEMS PATHOPHYSIOLOGY AND CLINICAL PRESENTATION

This video describes disorders of the neuromuscular junction, mechanisms of disease, and the pathophysiology, classification, and clinical presentation of LEMS.

Presented by Perry B. Shieh, MD, PhD
Department of Neurology
David Geffen School of Medicine at UCLA

CHAPTER 2 – DIAGNOSIS AND MISDIAGNOSIS IN LEMS

This video presents diagnostic approaches for LEMS, common misdiagnoses, and the expected progression of disease.

Presented by Perry B. Shieh, MD, PhD
Department of Neurology
David Geffen School of Medicine at UCLA

CHAPTER 3 – THE ROLE OF FIRDAPSE IN LEMS TREATMENT

This video provides a clinical overview of FIRDAPSE, including its MOA and the efficacy and safety results from two Phase 3 clinical trials.

Presented by Perry B. Shieh, MD, PhD
Department of Neurology
David Geffen School of Medicine at UCLA

CHAPTER 4 – ACCESS AND SUPPORT BENEFITS OF CATALYST PATHWAYS™

This video describes the suite of product access, financial assistance, and educational support services available to patients receiving FIRDAPSE therapy via the Catalyst Pathways program.

Presented by Dan Brennan
Chief Commercial Officer
Catalyst Pharmaceuticals, Inc.

This program and its materials have been sponsored by Catalyst Pharmaceuticals. The speaker has been compensated by Catalyst Pharmaceuticals to provide this presentation. This presentation is consistent with all applicable US Food and Drug Administration (FDA) requirements and the approved product labeling for FIRDAPSE. This program is not intended for continuing education credit for healthcare professionals. Any expenditures in relation to this event may be reported as required by state and federal spend-reporting requirements.

close video
close video
close video
close video

Indication & Important Safety Information

indications and usage:

FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

CONTRAINDICATIONS

FIRDAPSE is contraindicated in patients with:

  • A history of seizures
  • Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS

Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.

Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.

ADVERSE REACTIONS

The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References:
  1. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467-1474.
  2. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893-902.
  3. Data on file, Catalyst Pharmaceuticals.
  4. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann NY Acad Sci. 2003;998:500-508
  5. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
  6. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci. 2016;43(5):635-647.
  7. Mantegazza R, Meisel A, Sieb JP, et al. The European LEMS Registry: baseline demographics and treatment approaches. Neurol Ther. 2015;4(2):105-124.
  8. Harms L, Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530.
  9. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35-42.
  10. Oh SJ, Sieb JP. Update on amifampridine as a drug of choice in Lambert-Eaton myasthenic syndrome. US J Neurol. 2014;10(2):83-89.
  11. Strupp M, Teufel J, Zwergal A, et al. Aminopyridines for the treatment of neurologic disorders. Neurol Clin Pract. 2017;7(1):65-76.
  12. Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-349.
  13. Full Prescribing Information for FIRDAPSE (amifampridine). Catalyst Pharma; 2018.
  14. Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al; LEMS Study Group. Amifampridine phosphate (FIRDAPSE®) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53(5):717-725.

Indication & Important Safety Information

indications and usage:

FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

CONTRAINDICATIONS

FIRDAPSE is contraindicated in patients with:

  • A history of seizures
  • Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS

Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.

Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.

ADVERSE REACTIONS

The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References:
  1. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467-1474.
  2. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893-902.
  3. Data on file, Catalyst Pharmaceuticals.
  4. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann NY Acad Sci. 2003;998:500-508
  5. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
  6. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci. 2016;43(5):635-647.
  7. Mantegazza R, Meisel A, Sieb JP, et al. The European LEMS Registry: baseline demographics and treatment approaches. Neurol Ther. 2015;4(2):105-124.
  8. Harms L, Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530.
  9. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35-42.
  10. Oh SJ, Sieb JP. Update on amifampridine as a drug of choice in Lambert-Eaton myasthenic syndrome. US J Neurol. 2014;10(2):83-89.
  11. Strupp M, Teufel J, Zwergal A, et al. Aminopyridines for the treatment of neurologic disorders. Neurol Clin Pract. 2017;7(1):65-76.
  12. Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-349.
  13. Full Prescribing Information for FIRDAPSE (amifampridine). Catalyst Pharma; 2018.
  14. Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al; LEMS Study Group. Amifampridine phosphate (FIRDAPSE®) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53(5):717-725.